EPISODE · Aug 8, 2025 · 7 MIN
诺华或将收购Avidity，RNAi肌病赛道升温 -- 250807
from 生物科技 · host Rei
本期《Biotech快讯》聚焦一则重磅并购传闻：瑞士制药巨头诺华（Novartis）正考虑收购专注RNA干扰疗法的Avidity Biosciences。这家以抗体-寡核苷酸偶联技术（AOC）为核心的生物科技公司，近年来在杜氏肌营养不良（DMD）等神经肌肉疾病领域快速崛起，核心管线del-zota刚获得FDA突破性疗法认定，市值已达58亿美元。本期播客将带你了解Avidity的研发版图、为何吸引诺华青睐，以及这笔潜在交易背后的战略意义。RNA疗法赛道为何再度升温？诺华为何频频出手？答案，尽在本期内容。
Embed this episode
NOW PLAYING
诺华或将收购Avidity，RNAi肌病赛道升温 -- 250807
0:00
7:39
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of 生物科技?
This episode is 7 minutes long.
When was this 生物科技 episode published?
This episode was published on August 8, 2025.
Can I download this 生物科技 episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!